Buy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

What is Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for?

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a combination medication used for the long-term, once-daily, maintenance treatment of: ^[1]

• Patients with chronic obstructive pulmonary disease (COPD), including:
  • Patients with chronic bronchitis and/or emphysema
  • Patients on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations in whom additional treatment of airflow obstruction is desired
  • Patients who are already receiving umeclidinium and a fixed-dose combination of fluticasone furoate and vilanterol
• Asthma in patients aged 18 years and older.

It is available in inhaler form containing 2 foil strips, each with 30 blisters with powder intended for oral inhalation. One strip contains 100 or 200 mcg fluticasone furoate per blister, and the other strip contains a combination of 62.5 mcg umeclidinium and 25 mcg vilanterol per blister. A blister from each strip is used to create one dose.^[1]

How does Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) work?

COPD and asthma are chronic lung diseases that leads to lung inflammation and airway narrowing.^[2]

Trelegy Ellipta is a combination therapy that consists of three active ingredients:

• Fluticasone furoate is a synthetic trifluorinated inhaled corticosteroid (ICS) that works anti-inflammatory. It has a wide range of effects on multiple parts of COPD-related inflammation of the airways. ICS is a commonly used therapy used for the treatment of COPD.^[3]
• Umeclidinium is a long-acting muscarinic antagonist (LAMA), also called an anticholinergic. Anticholinergics work as a bronchodilator. This means they can relax the muscle cells in the lungs, and widen the airways. This so-called bronchodilation will make it easier for patients to breathe.^[4]
• Vilanterol is a long-acting beta2-adrenergic agonist (LABA). When inhaled, it functions as a bronchodilator. It does so by activating beta2 receptors, which are present on muscle cells of the lungs. This activation leads to relaxation of the cells of the airways.^[5]

When combined, efficacy of these substances provide better symptom reduction in maintenance therapy of COPD or asthma, and will improve quality of life.

Where has Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) been approved?

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) was approved by:

• The Food and Drug Administration (FDA), USA
  • On September 18, 2017 for the for the maintenance treatment of people with COPD.^[2]
  • September 10, 2020 for the treatment of asthma in adults^[8]
• The European Medicines Agency (EMA), Europe on November 15, 2017.^[6]
• The National Medical Products Administration (NMPA), China on November 8, 2019.^[7]

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) taken?

The standard dose range is:^[1]

• 100 mcg fluticasone furoate, 62.5 mcg umeclidinium and 25 mcg vilanterol for COPD and asthma
• An additional strength for asthma alone of 200 mcg fluticasone furoate, 62.5 mcg umeclidinium and 25 mcg vilanterol.^[8]

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is administered once daily by oral inhalation. It should be used at the same time every day, and it is not used more than once every 24 hours.

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) can increase the risk of fungal infections of the nose or mouth. Therefore, patients should rinse their mouth with water without swallowing after using Trelegy.

Complete information about Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) dosage and administration can be found in the official prescribing information listed in our references section.^[1]

Note: Please consult with your treating doctor for personalised dosing and potential drug interactions.

Are there any known adverse reactions or side effects of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)?

Common adverse reactions

The most common adverse reactions listed in the prescribing information include:^[1]

• Headache
• Nausea
• Vomiting
• Diarrhea
• Back pain
• Cough
• Taste disturbance
• Mouth and/or throat pain

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include:^[1]

• Fungal infection in your mouth or throat (thrush)
• Upper respiratory tract infection (pneumonia)
• Weakened immune system
• Reduced adrenal function (adrenal insufficiency)
• Sudden breathing problems immediately after inhalation
• Serious allergic reactions
• Various effects on the heart
• Various effects on the nervous system
• Bone thinning or weakness (osteoporosis)
• Various new or worsening eye problems
• Urinary retention
• Changes in laboratory blood values, including hyperglycemia and hypokalemia

Use in a specific population

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) can be fatal for a fetus, it is advised to avoid pregnancies and breastfeeding.^[1]

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.^[1]

References

1. Summary of Product Characteristics [FDA]: Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) [PDF] GlaxoSmithKline, Sept 18, 2017

2. FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of COPD
Press release, Sept 18, 2017

3. Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease
Falk, JA, Proc Am Thorac Soc, May 1, 2008

4. Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy
Babu KS, Ther Adv Chronic Dis., Apr 8, 2017

5. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies
Siler TM, Respiratory Medicine, Sept 2015

6. Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)
EMA official product page, last checked on Aug 10, 2020

7. The first triple therapy for COPD, in one single device Trelegy Ellipta, is approved in China
GSK press release, Nov 8, 2019

8. FDA approves Trelegy Ellipta as the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US
GSK press release, Sep 10, 2020